Syntara Limited · ASX:SNT
Syntara — Euroz Hartleys 2026 Healthcare Forum
15 slides from Syntara's conference presentation, Feb 5, 2026
Slide 1: Euroz Hartleys 2026 Healthcare Forum
For personal use only Euroz Hartleys 2026 Healthcare Forum Gary Phillips, CEO 5 February 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the d
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Australian-founded Backed by Multiple shots on Funded into 2027 with clinical stage specialist healthcare goal from additional near term data to drive drug developer. investors – Phase 2, Phase 1 and value over the next 43% institutional. preclinical asset
Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume – YTD Share price – 02 February 2026 $0.032 For personal use only Close 0.1 Market cap A$52.2m 0.08 Cash balance – 31 December 2025 A$12.3m 0.06 Enterprise value A$39.9m 0.04 0.02 Institutional Ownership 30 Sept 25 0 Volume D&
Slide 5: Syntara Board
SYNTARA BOARD Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Experienced senior global pharma • 30+
Slide 6: 2025 Achievements
2025 ACHIEVEMENTS • Lead asset amsulostat continues to build momentum • Amsulostat Phase 2a myelofibrosis clinical trial completed and presented at American For personal use only Society of Hematology Annual Meeting in Orlando • Two myelodysplastic syndrome (MDS) Phase 2 studies initiated with launc
Slide 7: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~15 in 1m people (fibrosis) in bone marrow and abnormal proliferation of worldwide (USA ~ 20,000 patie
Slide 8: Myelofibrosis: Limited treatment options currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat For personal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, clearing fibrosis from the bone marrow and (enlar
Slide 9: Total Symptom Score
TOTAL SYMPTOM SCORE Reduction at W24 Additional reduction past W24 73% (8/11) of patients achieved TSS50 at Week 24 or beyond * Pt continued past W38 # Pt completed W52 and study For personal use only Baseline TSS 37 10 52# 32 11* 18# 22# 45# 23# 10# 19# Symptom relief continues 0 for patients: TSS
Slide 10: Spleen Volume Reduction
SPLEEN VOLUME REDUCTION 44% (4/9) of patients achieved SVR25 at Week 24 or beyond For personal use only Improved spleen volume reduction: • At Week 24, 7/9 (78%) evaluable patients* experienced stable or reduced spleen volume with no increases in RUX dose. • 4/9 (44%) evaluable patients achieved SVR
Slide 11: Positive Top Line Phase 2a Data Highlights
POSITIVE TOP LINE PHASE 2A DATA HIGHLIGHTS AMSULOSTAT’S POTENTIAL IN MYELOFIBROSIS For personal use only Improvements of 50% or Meaningful spleen Of the 7 patients Next stage of amsulostat more in total symptom volume reductions that completed 52 clinical development and score (TSS50) (SVR) were obs
Slide 12: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / For personal use only DATE OF ANNOUNCEMENT DEC-2024 FEB-2024 JUNE-2023 JULY-2022 Drug Name Elritercept Pelabresib Pacritinib Momelotinib Lead Indication / MDS and MF Myelofibrosis Myelofibrosis Myelofibrosis Phase (at transaction
Slide 13: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS For personal use only PARTICIPANTS FDA approved development plan Myelofibrosis and partner engagement High Risk MDS Interim safety and Phase 2 initiation AZAL
Slide 14: 2026 Outlook Webinar
2026 – Outlook Webinar: Held on 3rd February 2026 Participants For personal use only Hashan De Silva Gary Phillips Non Executive Director CEO Link to webinar: https://youtu.be/XiWqRdZKWhE 14
Slide 15: For personal use only
For personal use only Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au gary.phillips@syntaraTX.com.au